We have launched 4 self-developed monoclonal antibody (mAb) biosimilars including the first Chinese biosimilar HANLIKANG (rituximab), HANQUYOU (trastuzumab) a China-developed mAb biosimilar approved in China, Europe and U.S., and HANDAYUAN (adalimumab), and HANBEITAI (bevacizumab), navigating at the forefront of Chinese biopharmaceutical industry.
We continue the momentum for a diversified innovation by enhancing internal innovation capacities and reaching out to more strategic partners. We have been replenishing our innovation pipeline with HANSIZHUANG (serplulimab injection, anti-PD-1 mAb) as backbone.
Adopting "Combo+Global" differentiation strategy, we have versatile in-house combination therapy portfolio with serplulimab (anti-PD-1 mAb) as backbone. Multiple clinical trials are underway (including 3 international multi-centre clinical trials).
Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 50 molecules including monoclonal antibody (mAb), multispecific antibody, antibody-drug conjugate (ADC), fusion protein, small molecule drug, etc..
We have 3 manufacturing facilities, namely Xuhui Site, Songjiang Site I and Songjiang Site II. Our commercial capacity totals 48,000L. The fully operational sites and quality management systems are GMP-certificated by China, the EU and U.S. regulatory agencies.
We have built an in-house commercial team focused on domestic market, covering marketing, access, channel, pricing, strategy and sales and compromising of over 1500 professionals; we have also joined forces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide.
